ACTRN12614000442606
Terminated
N/A
Treatment with Continuous Positive Airway Pressure in people aged 50-80 years with Obstructive Sleep Apnoea and Mild Cognitive Impairment to reduce the rate of cognitive decline
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity of Sydney
- Enrollment
- 29
- Status
- Terminated
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •To be eligible, participants must:
- •1\. Have the presence of at least moderate OSA as defined by an AHI of greater than or equal to 15 as defined by PSG using the criteria of 4% O2 desaturation for events.
- •2\. Have a diagnosis of single\- or multi\-domain Mild Cognitive Impairment (MCI) as determined by neuropsychological examination using a standardized research neuropsychological battery.
- •3\. Have stability of at least four weeks on permitted medications (i.e. medications known not to affect sleep architecture or circadian rhythms).
- •4\. Be fluent in English
- •5\. Be willing and able to complete baseline, three month and six month outcome measures
- •6\. Be willing to send in CPAP Smartcard for adherence testing
Exclusion Criteria
- •Participants will be excluded if they have:
- •1\. Suspected dementia or a score of \<24 on the Mini\-Mental State Examination
- •2\. A history of cerebrovascular events (e.g., stroke, TIA)
- •3\. Planned shift\-work or transmeridian travel within timeline of study (six months from baseline)
- •4\. A diagnosis of neurological disorders (e.g. Parkinson's Disease, Epilepsy, Multiple Sclerosis)
- •5\. Head trauma with associated loss of consciousness \> 30mins or head injury with persisting cognitive deficits
- •6\. Psychiatric disorders including current major depression; Bipolar Disorder (I and II); schizophrenia
- •7\. Been taking tricyclic antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), benzodiazepines, sedative hypnotics, antipsychotics, mood stabilisers, modafinil or stimulants, cholinesterase inhibitors or medications known to affect sleep architecture and/or circadian rhythms (e.g. Lithium)
- •8\. Current substance abuse or dependence (alcohol and/or other illicit substances)
- •9\. Any significant systematic illness or medical condition that may hinder compliance with treatment protocol
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Treatment by uninterrupted positive airway pressure by nasal route - Evaluation of REMstar® Auto with C-Flex in clinical practiceSleep apnoea/ hypopnoea syndromeNervous System DiseasesSleep disordersISRCTN59353477Respironics International (France)20
Completed
N/A
Continuous positive airway pressure therapy withdrawal - a model to evaluate treatment modalities for sleep apnoeaObstructive sleep apnoeaNervous System DiseasesSleep disordersISRCTN93153804niversity Hospital of Zurich (Switzerland)40
Completed
N/A
CPAP treatment in stroke patients with OSADiseases of the nervous systemKCT0003688Chungnam National University Hospital80
Completed
N/A
Can early treatment prevent obstructive sleep apnoea-related brain damage?Moderate obstructive sleep apnoea (between 15 and 29 hypopnoea or apnoea events per hour during sleep).Sleep apnoea-related brain damage.Neurological - Other neurological disordersRespiratory - Sleep apnoeaACTRN12614001202651Dr. Carrie Innes45
Completed
N/A
The effect of Continuous Positive Airway Pressure (CPAP) on the collapsed lung during single-lung-ventilation in patients undergoing robot-assisted thoracoscopic esophageal resection: pulmonary complications, local and systemic cytokine productioEsophageal cancerCancerOesophagealISRCTN61458115niversity Medical Center Utrecht (UMCU), Department of Surgery (The Netherlands)30